Field strength and gadolinium enhancement in the clinical setting

Prager, Jordan M.; Rosenblum, Jordan D.; Kim, D.; Karczmar, G. S.; Lowe, Gina M.; Tomiak, Myrosia M.; Huddle, D. C.; Ramsey, Ruth G.

doi:10.1007/978-3-642-79434-6_257

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4). For both single-dose and double-dose studies, the lesion-to-brain contrast-to-noise ratios were nearly a factor of two higher at 2.0 T than at 0.5 T. Similar conclusions were also drawn by Prager et al [6], who measured enhancing cranial lesions at 0.1 T, 0.3 T, and 1.5 T.…”

Section: Field Strength Dependency Of Gadolinium Enhancementsupporting

confidence: 73%

How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence

Elster

1997

Eur Radiol

View full text Add to dashboard Cite

The overwhelming majority of published studies defining the clinical utility of gadolinium administration for neuroimaging have been performed at high field using conventional spin-echo imaging. Concerning the issue of field strength, several investigations have now shown that for a given dose of contrast, enhancement is less apparent at low field than at high field. Concerning the issue of pulse sequence, there is now convincing clinical and experimental evidence that all T1-weighted sequences are not equal in demonstrating contrast enhancement. Specifically, T1-weighted spoiled gradient-echo sequences do not show the same degree of visually apparent contrast enhancement compared to conventional spin-echo sequences. The use of magnetization transfer techniques which demonstrate areas of enhancement unseen on conventional pulse sequences is also addressed.

show abstract

Section: Field Strength Dependency Of Gadolinium Enhancementsupporting

confidence: 73%

How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence

Elster

1997

Eur Radiol

View full text Add to dashboard Cite

show abstract

Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents

1999

View full text Add to dashboard Cite

The relaxivities r1 and r2 of magnetic resonance contrast agents and the T1 relaxation time values of tissues are strongly field dependent. We present quantitative data and simulations of different gadolinium-based extracellular fluid contrast agents and the modulation of their contrast enhancement by the magnetic field to be able to answer the following questions: How are the dose and field dependences of their contrast enhancement? Is there an interrelationship between dose and field dependence? Should one increase or decrease doses at specific fields? Nuclear magnetic relaxation dispersion data were acquired for the following contrast agents: gadopentetate dimeglumine, gadoterate meglumine, gadodiamide injection, and gadoteridol injection, as well as for several normal and pathological human tissue samples. The magnetic field range stretched from 0.0002 to 4.7 T, including the entire clinical imaging range. The data acquired were then fitted with the appropriate theoretical models. The combination of the diamagnetic relaxation rates (R1 = 1/T1 and R2 = 1/T2) of tissues with the respective paramagnetic contributions of the contrast agents allowed the prediction of image contrast at any magnetic field. The results revealed a nearly identical field and dose-dependent increase of contrast enhancement induced by these contrast agents within a certain dose range. The target tissue concentration (TTC) was an important though nonlinear factor for enhancement. The currently recommended dose of 0.1 mmol/kg body weight seems to be a compromise close to the lower limits of diagnostically sufficient contrast enhancement for clinical imaging at all field strengths. At low field contrast enhancement might be insufficient. Adjustment of dose or concentration, or a new class of contrast agents with optimized relaxivity, would be a valuable contribution to a better diagnostic yield of contrast enhancement at all fields.

show abstract

Field strength and gadolinium enhancement in the clinical setting

Cited by 2 publications

References 2 publications

How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence

How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence

Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents

Contact Info

Product

Resources

About